FDA Approves TEVIMBRA for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma Gastrointestinal 3 Mins Read March 4, 2025 New Treatment Option for ESCC PatientsThe U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) in…
FDA Grants Accelerated Approval to Zanubrutinib (Brukinsa) for Relapsed or Refractory Follicular Lymphoma Lymphoma 2 Mins Read On March 7, 2024, the Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib, marketed as Brukinsa by BeiGene…
Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL / SLL Mehrdad Mobasher MD Chronic Lymphocytic Leukemia 8 Mins Read Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL/SLL Mehrdad Mobasher MD By Mehrdad Mobasher, MD, MPH The ALPINE study was a…
